Clinical Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China.
Clinical Laboratory, Nanxun District Hospital of Traditional Chinese Medicine, Huzhou, Zhejiang, China.
Front Immunol. 2024 Aug 15;15:1416068. doi: 10.3389/fimmu.2024.1416068. eCollection 2024.
The efficiency of systemic immune-inflammation index (SII) in predicting prognosis of osteosarcoma (OSA) patients has been extensively analyzed, but no consistent findings are obtained. Therefore, this meta-analysis focused on identifying the precise prognostic value of SII for OSA.
We comprehensively searched electronic databases of PubMed, Embase, Web of Science, Cochrane Library, and China National Knowledge Infrastructure (CNKI) from inception to 24 February, 2024. Meanwhile, the efficiency of SII in predicting prognosis of OSA was evaluated by calculating pooled hazard ratios (HRs) as well as 95% confidence intervals (CIs). Additionally, the correlation of SII with the OSA clinicopathological characteristics was analyzed based on pooled odds ratios (ORs) and 95%CIs.
Six studies with 1015 cases were enrolled into this work. According to the combined data, the higher SII was markedly related to poor overall survival (OS) (HR=2.01, 95%CI=1.30-3.09, p=0.002) and Enneking stage III (OR=2.21, 95%CI=1.11-4.39, p=0.024) of patients with OSA. Nonetheless, SII was not significantly related to gender, age, pathological fracture, tumor size, tumor location, tumor differentiation, and metastasis in patients with OSA.
In summary, the higher SII is markedly related to poor OS and advanced Enneking stage in OSA patients.
https://inplasy.com/inplasy-2024-7-0107/, identifier INPLASY202470107.
系统免疫炎症指数（SII）在预测骨肉瘤（OSA）患者预后中的效率已被广泛分析，但未得出一致的结论。因此，本荟萃分析旨在确定 SII 对 OSA 的确切预后价值。
我们全面检索了 PubMed、Embase、Web of Science、Cochrane 图书馆和中国知网（CNKI）从创建到 2024 年 2 月 24 日的电子数据库。同时，通过计算合并风险比（HRs）及其 95%置信区间（CIs）来评估 SII 预测 OSA 预后的效率。此外，还基于合并优势比（ORs）及其 95%CIs 分析了 SII 与 OSA 临床病理特征的相关性。
本研究纳入了 6 项研究共 1015 例患者。根据汇总数据，较高的 SII 与较差的总生存率（OS）（HR=2.01，95%CI=1.30-3.09，p=0.002）和 OSA 患者的 Enneking 分期 III（OR=2.21，95%CI=1.11-4.39，p=0.024）显著相关。然而，SII 与 OSA 患者的性别、年龄、病理性骨折、肿瘤大小、肿瘤位置、肿瘤分化和转移无显著相关性。
总之，较高的 SII 与 OSA 患者较差的 OS 和较高的 Enneking 分期显著相关。
https://inplasy.com/inplasy-2024-7-0107/，标识符 INPLASY202470107。
